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Abstract
Aim: The object of this work was to study how National Health Service hospitals in 
England and Wales aimed to maintain effective and safe colorectal cancer (CRC) services 
during the first peak of the COVID- 19 pandemic (April 2020).
Method: A national survey was performed among all 148 hospitals providing CRC ser-
vices. Information was collected about changes in referrals, diagnostic, staging and thera-
peutic procedures, as well as whether there was access to a ‘cold site’ (a hospital facility 
free of COVID- 19). Clinicians in each hospital were also asked to give the ‘single most 
important lesson learned’ about keeping services safe and effective.
Results: Full responses were received from 123 (83%) hospitals, and information about ‘cold 
sites’ was available for 146 (99%). Eighty hospitals (54%) had access to a ‘cold site’ and this was 
increased in regions with higher COVID- 19 infection rates (p <0.001). Of the 123 responding 
hospitals, 105 (85%) indicated that referrals of patients with suspected CRC had dropped by 
at least 30%, and 69 (56%) indicated that treatment plans were altered in at least 50% of CRC 
patients. However, ‘cold site’ availability protected the capacity for diagnostic colonoscopy 
(p = 0.013) and CRC resection (p = 0.010). Many ‘lessons learned’ highlighted the importance of 
adequate structural service organization, often mentioning ‘cold sites’ and regional coordina-
tion as examples, good communication and triage of patients based on clinical urgency.
Conclusion: Access to ‘cold sites’, as well as regional coordination, clear communication 
and strong leadership, were found to be pivotal in maintaining capacity for diagnosis and 
treatment of CRC during the COVID- 19 surge.
K E Y W O R D S
cold site, colorectal cancer, COVID- 19
What does this paper add to the literature?
NHS hospitals providing colorectal cancer services in England and Wales have demonstrated that 
access to ‘cold sites’ helped to protect capacity for diagnostic colonoscopy and colorectal cancer 
resection during COVID- 19. The ‘lessons learned’ highlight the importance of adequate structural 
organization, good communication and triage of patients based on urgency
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INTRODUC TION
The first peak of the COVID- 19 pandemic had a large impact on colo-
rectal cancer (CRC) services in many countries. Early reports suggest 
that patients undergoing cancer treatments were at increased risk of 
COVID- 19 infection, the requirement for critical care, and mortality 
[1– 3]. Despite the roll- out of vaccination programmes, the COVID- 19 
pandemic continues to disrupt CRC services due to the direct risks 
of COVID- 19 to vulnerable CRC patients as well as the diversion of 
resources to other areas in the healthcare system, increased levels 
of staff sickness, and the need for social isolation among the clinical 
workforce [4,5].
Diagnostic delays as a result of suspended screening pro-
grammes, reduced access, and availability for diagnostic services 
and changes in health- seeking behaviours due to fear of exposure 
to COVID- 19 have sparked concerns that a rise in late cancer diag-
noses may increase cancer mortality in the long term [6]. For exam-
ple, in the UK, urgent primary care referrals for suspected cancer 
dropped by 60% in April 2020 compared with the previous year, 
and modelling exercises have estimated that diagnostic delays may 
lead to an increase of up to 16.6% in avoidable deaths from CRC 
[7,8].
To maintain treatment capacity and to protect patients during 
the COVID- 19 pandemic, cancer services have increased the use 
of nonoperative treatments [9] and created ‘cold sites’ for elec-
tive treatments [10]. ‘Cold sites’ are hospital facilities set up to 
be COVID- 19 free, or almost so. This environment was achieved 
in the initial wave by screening patients for COVID- 19 prior to 
admission, strict segregation of elective and emergency surgical 
services, and geographical separation of the ‘cold’ facility from 
where patients with COVID- 19 were treated. More recently, reg-
ular staff testing for asymptomatic COVID- 19 has also been used 
[11,12].
The National Bowel Cancer Audit (NBOCA) carried out a national 
study of CRC services during COVID- 19 to map the response of the 
National Health Service (NHS) in England and Wales. The primary 
aim of the study was to assess the capacity for elective CRC surgery 
and diagnostic colonoscopy in relation to the provision of ‘cold sites’ 
during the first peak of the pandemic. These results were compared 
at a regional level to assess whether the availability of ‘cold sites’ for 
CRC surgery varied according to local COVID- 19 infection rates. We 
also created a national snapshot of the impact of the pandemic on 
other aspects of CRC diagnostic and treatment pathways in England 
and Wales.
In addition, we asked the CRC providers to describe the ‘single 
most important lesson learned’ about how to make services for CRC 
patients as safe and effective as possible during the COVID- 19 pan-
demic. We present these lessons according to whether they relate 
to the diagnostic and staging aspect or the therapeutic aspect of the 
CRC treatment pathway, COVID- 19- specific measures, the struc-
tural organization of CRC services, or leadership and management 
(human factors).
METHOD
Regional cumulative COVID- 19 rates
Total confirmed ‘cumulative’ COVID- 19 diagnoses from 11 January 
2020 to 15 April 2020 were obtained for English local authorities 
and Wales [13]. For England, local authorities were mapped to the 
21 regions that represent the NHS Cancer Alliances, the organiza-
tional structures set up to enable cancer care to be more effectively 
planned across local cancer care pathways [14]. Regional cumula-
tive COVID- 19 rates to 15 April 2020 per 100 000 population were 
calculated using English and Welsh population estimates [15].
National survey
All 148 NHS English hospital trusts and Welsh hospital boards pro-
viding CRC care in England and Wales according to the NBOCA were 
requested in June and July 2020, via a national survey, to provide 
information about the CRC services they provided in mid- April 2020 
(see Appendix 1). The survey was distributed to leading NBOCA cli-
nicians, and was therefore predominantly completed by consultant 
colorectal surgeons.
NHS hospital trusts and hospital boards are the legal entities re-
sponsible for providing publicly funded secondary care in England 
and Wales, respectively. A hospital trust or hospital board can con-
sist of one or more hospital sites, but in this paper, ‘hospital’ is used 
to refer to a hospital trust or hospital board.
The requested information covered five COVID- 19- related 
changes with respect to numbers of referrals for newly diagnosed 
patients, planned CRC treatments, delivery of CRC services, access 
to COVID- 19 surgical ‘cold sites’, and the ‘single most important les-
son learned’ (Appendix 1). The ‘lessons learned’ were provided as 
free text.
Quantitative analysis
The regional cumulative COVID- 19 rates were grouped into high 
and low based on a threshold corresponding to the overall median 
value of cumulative COVID- 19 rates for the English Cancer Alliances 
and Wales. English hospitals were assigned to a group according to 
which Cancer Alliance they are in. The two hospitals with missing 
data for access to a ‘cold site’ were considered not to have such ac-
cess for the purposes of further analysis.
The primary outcome for the study was the capacity to maintain 
elective CRC surgery and diagnostic colonoscopy dependent on the 
provision of ‘cold sites’.
Chi- square tests were used to compare proportions. Spearman's 
rank correlation coefficient was used to test the association be-
tween cumulative COVID- 19 rates and access to surgical ‘cold sites’. 
The level of statistical significance was set at 0.05.
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Free- text analysis
The free- text responses to the ‘single most important lesson learned’ 
were independently analysed by two reviewers (JB and JvdM) in 
three steps. First, responses were broken down into statements. If 
responses contained more than one statement these were analysed 
separately. Second, the statements were grouped into broader ‘les-
sons learned’. Each statement could link to multiple ‘lessons learned’ 
if applicable. Third, the ‘lessons learned’ were organized into five 
categories (diagnostic and staging pathway, treatment pathway, 
COVID- specific measures, structural organization, leadership and 
management) and linked to five generally recognized domains of 
healthcare quality which were defined a priori: ‘effectiveness’ (de-
livering care to all patients who are expected to benefit); ‘safety’ 
(avoiding harm to patients from care that is intended to help them); 
‘efficiency’ (avoiding waste of facilities, equipment and staff); ‘re-
sponsiveness’ (responding to patients’ specific conditions and situa-
tions); and ‘patient experience’ (providing care that is respectful and 
guided by patient preferences) [16]. The ‘lessons learned’ could link 
to more than one domain as appropriate. Disagreements were re-
solved through discussion.
RESULTS
Full responses were received from 123 (83%) hospitals. Information 
about ‘cold sites’ was available for 146 (99%).
Cumulative COVID- 19 rates and access to surgical 
‘cold sites’
Overall, 80 of the 148 hospitals (54%) were found to have access 
to ‘cold sites’ for CRC surgery (Table 1, Figure 1). Over half of 
these (41 hospitals), reported access to a ‘cold site’ in the inde-
pendent sector. There was considerable regional variation among 
the 21 English regions and Wales. In four of these 22 regions 
(18%), 25% or fewer of the hospitals had access to a ‘cold’ site, 
and in four regions (18%), all hospitals had access to such a site. 
There was strong evidence of an association between the regional 
cumulative COVID- 19 infection rate per 100 000 population and 
the proportion of providers reporting access to surgical ‘cold sites’ 
(p < 0.001) (Figure 2).
Referrals
The majority of hospitals reported a significant reduction in the 
number of urgent referrals: only 6 of the 123 hospitals (5%) that 
 responded reported no reduction (more than 90% of the usual 
number of referrals), 12 hospitals (10%) reported a small reduction 
in numbers (71% to 90% of the usual number), 95 hospitals (77%) 
reported a large reduction in numbers (20% to 70% of the usual of 
number) and 10 hospitals (8%) reported very few referrals (0% to 
19% of the usual number).
Changes to planned CRC treatments
Of the 123 responding hospitals, 69 (56%) indicated that, in response 
to COVID- 19 risks, treatment plans had been altered in more than 50% 
of their patients (Figure 3). Again, considering changes that affected 
more than 50% of their patients, 61 hospitals (50%) reported delays 
in treatments due to COVID- 19 infection risks, 61 (50%) delays in tis-
sue diagnosis and radiological staging, and 57 (46%) delays in treat-
ment due to diversion of resources. The COVID- 19 pandemic had a 
smaller impact on the length and type of chemotherapy treatment (47 
hospitals (38%) reported changes in more than 50% of their patients), 
and on the use of temporizing treatments (23 hospitals (19%) reported 
changes in more than 50% of their patients) such as the stenting of ob-
structing cancers and radiotherapy for rectal cancer with a ‘long wait’.
Changes to provision of CRC services
The majority of providers reported that CRC services were running 
at less than 70% of their usual capacity for diagnostic and thera-
peutic activity (Table 2). Among the 123 responding hospitals, com-
plete cessation of activity (0% to 10% of usual activity) was reported 
by 95 hospitals (77%) for diagnostic colonoscopy, 72 (59%) for lung 
resection, 67 (54%) for liver resection, 28 (23%) for CRC resection, 
22 (18%) for adjuvant chemotherapy, and 21 (17%) for neo- adjuvant 
chemoradiotherapy.
There was no statistically significant association between 
high regional COVID- 19 rates and the provision of CRC services 
(Table 2). However, providers with access to ‘cold sites’ for CRC 
surgery were significantly more likely to retain higher levels of 
activity for diagnostic colonoscopy (p = 0.013), CRC resection 
(p = 0.010), lung resection (p = 0.026), neo- adjuvant chemoradio-
therapy (p = 0.010) and adjuvant chemotherapy (p = 0.050), with 
weaker statistical evidence for a similar difference for liver resec-
tion (p = 0.096) (Table 3).
Single most important lesson learned
We received 108 responses, from which 154 statements were ex-
tracted. If responders had included multiple statements these were 
analysed separately (see Method section) (Figure 4). These statements 
were mapped to 31 ‘lessons learned’, with frequencies of statements 
classified as each lesson. Five statements could not be classified.
Fifty statements related to the structural organization of the 
CRC services and 33 of these highlighted the importance of the 
use of ‘cold sites’. Thirty eight statements related to leadership and 
management with 12 mentioning aspects of communication and co-
ordination and eight the role of virtual (e.g. electronic) methods of 
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communication. Forty three statements related to aspects of the di-
agnostic and staging pathway with 21 focusing on the importance of 
triaging patients according to the urgency of their condition. Twelve 
statements related to aspects of the treatment pathway and 10 to 
COVID- specific minimization measures.
Based on the five domains of healthcare quality (see Method 
section), the ‘lessons learned’ were most frequently linked to ‘effec-
tiveness’ (87 statements), ‘efficiency’ (85 statements), and ‘safety’ (61 
statements). Less frequently the ‘lessons learned’ were linked to ‘pa-
tient experience’ (22 statements) and ‘responsiveness’ (21 statements).
DISCUSSION
Main findings
During the first 2 months of the COVID- 19 pandemic there was 
considerable regional variation in the availability of ‘cold sites’ 
for CRC surgery in England and Wales, with just over half of NHS 
hospitals reporting access. ‘Cold sites’ were more likely to be avail-
able in regions with higher COVID- 19 rates, and their availability 
was significantly linked to higher retained levels of CRC surgery.
About three- quarters of hospitals providing CRC services re-
ported a major drop in referrals, and just over half indicated that 
treatment plans were altered in at least 50% of their patients, mainly 
because of delays in staging investigations and initiation of treat-
ments. However, the availability of a ‘cold site’ also protected diag-
nostic colonoscopy activity, as well as other therapeutic activities 
including oncological treatments and the surgical management of 
advanced disease.
Many of the ‘lessons learned’ related to the structural organi-
zation of CRC services, with the setup of ‘cold sites’ often being 
mentioned as an example, and to human factors such as how the 
services were managed and led, highlighting the importance of com-
munication and regional coordination. The ‘lessons learned’ that had 
a direct clinical perspective focused more frequently on the diagnos-
tic and staging pathways than on the treatment pathway, reflecting 
major concerns about delays in the initiation of treatment for CRC.
TA B L E  1  Response rate and access to ‘cold sites’ for colorectal cancer surgery by English region and Wales, ranked according to 
cumulative COVID- 19 rate per 100 000 population mid- April 2020
English regions and Wales
Cumulative COVID−19 
rate per 100 000 
population
No. of hospitals providing 
CRC services
No. with surgical ‘cold 
site’ access (%)
No. of complete 
responders (%)
England and Wales 159.0 148 80 (54) 123 (83)
Peninsula 65.2 5 1 (20) 4 (80)
Somerset, Wiltshire, Avon and 
Gloucestershire
85.4 8 5 (63) 8 (100)
Humber, Coast and Vale 86.0 4 0 (0) 3 (75)
East of England – North 86.3 7 2 (29) 6 (86)
West Yorkshire and Harrogate 105.1 6 0 (0) 6 (100)
East Midlands 105.9 6 3 (50) 4 (67)
Wessex 107.9 8 3 (38) 6 (75)
Surrey and Sussex 130.8 9 3 (33) 8 (89)
Kent and Medway 144.6 4 2 (50)a  1 (25)
Thames Valley 144.7 4 2 (50) 4 (100)
East of England – South 149.3 8 4 (50)a  5 (63)
West Midlands 151.5 14 9 (64) 12 (86)
Greater Manchester 183.2 8 6 (75) 8 (100)
Lancashire and South Cumbria 190.8 4 1 (25) 4 (100)
South Yorkshire and Bassetlaw 193.1 5 3 (60) 5 (100)
Northern 195.8 8 5 (63) 5 (63)
Cheshire and Merseyside 201.3 9 7 (78) 7 (78)
North Central London 204.7 4 4 (100) 2 (50)
North East London 212.1 3 3 (100) 3 (100)
Wales 226.0 11 4 (36) 10 (91)
RM Partners (West London) 256.3 9 9 (100) 8 (89)
South East London 272.9 4 4 (100) 4 (100)
a These regions each had a single nonresponder. The nonresponders were assumed not to have access to ‘cold sites’.
Bold values indicate the overarching results for the whole of England and Wales.
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Methodological considerations
The main limitation of this study is that the mapping of ‘cold sites’ 
is based on reports from clinicians at a time when there was no 
generally accepted definition of a ‘cold site’. Clinicians may have 
over- reported the availability of ‘cold sites’ because this would have 
supported the local continuation of CRC services. Second, this study 
used responses from clinicians collected during the initial peak of the 
F I G U R E  1  Map of reported ‘cold sites’ for colorectal cancer surgery by English region and Wales
Cumulative COVID-19 rate per  
100,000 population on 15/04/20
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pandemic and therefore represents a time of greatest uncertainty 
with rapidly evolving and changing guidance. However, our results 
have enduring implications as they confirm the role of ‘cold sites’ in 
the maintenance of CRC surgery and diagnostic colonoscopy. Third, 
we were only able to establish COVID- 19 infection rates for Cancer 
Alliances rather than individual hospitals. We expect that if we could 
have captured infection rates at the hospital level our results would 
have shown stronger associations.






























































































































































































































































































English region and Wales
COVID-19 rate % 'cold site'
F I G U R E  3  Impacts of the COVID- 19 pandemic on the management of colorectal cancer patients in England and Wales
0 10 20 30 40 50 60 70 80 90 100
Treatment plans altered to reflect increased
risks from Covid-19 during pandemic
Changes in lengths of treatment
and/or choices of chemotherapy
Delays in treatment due to risk of
Covid-19 infection to patient
Delays in treatment due to diversion of
healthcare resources for Covid-19 care/preparation 
Delays in tissue diagnosis and/or staging investigations
Temporising treatments used e.g. stent,
rectal radiotherapy and long wait
Almost none or none (0 to 10%) Minority of patients (11 to 50%)
Majority of patients (51-90%) All or almost all patients (91-100%)
    |  1739BOYLE Et aL.
This study had an excellent response rate and therefore provides 
a representative picture of NHS hospitals delivering CRC services in 
England and Wales. An earlier national survey pertaining to UK CRC 
services during the pandemic included just 36 hospitals and primar-
ily evaluated adherence to national guidelines [17].
Surgical ‘cold sites’
A key finding from this work, in line with other studies [18– 20], is the 
pivotal role of ‘cold sites’ in maintaining CRC surgery. This is further 
supported by recent findings that patients undergoing elective can-
cer surgery at COVID- 19 ‘cold sites’ have lower rates of pulmonary 
complications and mortality [10]. As mentioned earlier, ‘cold sites’ 
were not precisely defined at the time we collected our data. Since, a 
broad definition has emerged that describes ‘cold sites’ as a COVID- 
19- free environment, either as a separate hospital or as separate fa-
cilities within a hospital, including an elective operating room, critical 
care and inpatient ward areas that are not shared with patients with 
COVID- 19 [10].
Additional measures employed to maintain these ‘cold sites’ have 
included pre- and postoperative self- isolation for 14 days, preopera-
tive COVID- 19 testing, including chest imaging, personal protective 
equipment (PPE) and workforce isolation with frequent and efficient 
point- of- care testing [11,12].
Single- centre studies have reported the use of nearby inde-
pendent sector facilities, as found within our study [11,12,21]. 
However, the disadvantages of using geographically separate 
sites might include a lack of acute care facilities and the absence 
of a fixed workforce having a negative affect on the continu-
ity of care. Careful risk assessment and selection for surgery, as 
well as clear communication regarding named clinician practice 
are vital.
Regions with higher rates of COVID- 19 were more likely to have 
access to ‘cold sites’. This may be explained by urban areas, with 
initially higher rates of COVID- 19, being more likely to have access 
to surgical ‘cold sites’ due to a higher density of NHS hospitals and 
greater availability of hospitals in the independent sector, such as 





Cumulative COVID- 19 rate
High (%) Low (%) p- value
Diagnostic colonoscopy activity
0%– 10% of usual 95 (77) 50 (74) 45 (82)
11%– 70% of usual 26 (21) 17 (25) 9 (16) 0.505
71%– 100% of usual 2 (2) 1 (1) 1 (2)
Colorectal resection activity
0%– 10% of usual 28 (23) 17 (25) 11 (20)
11%– 70% of usual 53 (43) 27 (40) 26 (47) 0.671
71%– 100% of usual 42 (34) 24 (35) 18 (33)
Liver resection activity
0%– 10% of usual 67 (54) 39 (57) 28 (51)
11%– 70% of usual 40 (33) 20 (29) 20 (36) 0.708
71%– 100% of usual 16 (13) 9 (13) 7 (13)
Lung resection activity
0%– 10% of usual 72 (59) 43 (63) 29 (53)
11%– 70% of usual 36 (29) 17 (25) 19 (35) 0.462
71%– 100% of usual 15 (12) 8 (12) 7 (13)
Neo- adjuvant chemoradiotherapy activity
0%– 10% of usual 21 (17) 9 (13) 12 (22)
11%– 70% of usual 65 (53) 39 (57) 26 (47) 0.383
71%– 100% of usual 37 (30) 20 (29) 17 (31)
Adjuvant chemotherapy activity
0%– 10% of usual 22 (18) 11 (16) 11 (20)
11%– 70% of usual 79 (64) 47 (69) 32 (58) 0.433
71%– 100% of usual 22 (18) 10 (15) 12 (22)
TA B L E  2  Provision of colorectal 
cancer services in mid- April by cumulative 
COVID- 19 rate
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Our results have also shown that ‘cold sites’ have a pivotal role in 
maintaining diagnostic activity, which is especially important given 
the 90% drop in endoscopy numbers in the initial phase of the pan-
demic [22,23]. The risk of contracting COVID- 19 during colonoscopy 
has subsequently been deemed low [24].
Changes to CRC care pathways
Widespread disruptions to activity within CRC care pathways were 
reported, especially with respect to treatment delays and adjust-
ments to standard pathways of patient care. Our results have shown 
that treatment plans tended to be delayed rather than alternative 
non- conventional treatments used. This is an important finding, as 
delays in treatment of just 4 weeks have been shown to have nega-
tive impacts on survival [25].
It is important to note that changes to planned CRC treatments 
and activity levels were independent of regional COVID- 19 infec-
tion rates, which is in line with earlier findings [26]. This may be ex-
plained by the greater availability of ‘cold sites’ in regions with higher 
COVID- 19 rates. However, it could also be explained by the impact 
of rapidly changing national guidelines during the first wave of the 
pandemic [27– 30]. For example, initially only emergency and urgent 
CRC surgery were prioritized and laparoscopic surgery was discour-
aged [27,31].
Ethical issues, especially those regarding the fairness of the 
allocation of resources that became scarce during the COVID- 19 
pandemic, need to be explicitly addressed [32]. This is in line with 
our finding that many ‘lessons learned’ reported by participating cli-
nicians related specifically to decisions about access to treatments. 
Strategies to minimize harm and prioritize patient care include using 
frailty and prognostic scoring in primary and secondary care in order 
to identify those patients for whom palliative care may be more ap-
propriate [33].
Adjustments to treatment pathways could also include, for ex-
ample, changes to oncological practice. Early guidance aimed to bal-
ance the risks of immunosuppression and the benefits of treatment 
against the risks of COVID- 19 infection, as well considering the ef-
fects on resource prioritization. In the context of CRC, these guide-
lines aimed to prioritize adjuvant chemotherapy instead of palliative 
chemotherapy [29]. A significant increase in the use of short- course 
radiotherapy for rectal cancer was also observed during this period 
[34].
Human factors
Our results demonstrate the importance that clinicians placed 
on key human factors, including communication, coordina-
tion and leadership, during the first wave of the pandemic 
[35]. Human factor principles can help us understand the in-
teraction  between humans and other elements of a system in 
order to improve safety, which is particularly important for a 
healthcare  system under stress [36]. For example, communi-
cation  during the COVID- 19 pandemic may be negatively af-
fected by the need to use PPE, workforce stress and fatigue, 
and  unfamiliar working  environments. We found that clinicians 
felt that a  well- led and responsive organization is better able 
to plan the most appropriate response to these challenging 
circumstances.
TA B L E  3  Provision of colorectal cancer services in mid- April by 
the availability of surgical ‘cold sites’
Response rate 
(%) (n = 123)
Surgical ‘cold site’ 
access
P valueYes (%) No (%)
Diagnostic colonoscopy activity
0%– 10% of 
usual
95 (77) 39 (66) 56 (88)
11%– 70% of 
usual
26 (21) 18 (31) 8 (13) 0.013
71%– 100% of 
usual
2 (2) 2 (3) 0 (0)
Colorectal resection activity
0%– 10% of 
usual
28 (23) 7 (12) 21 (33)
11%– 70% of 
usual
53 (43) 26 (44) 27 (42) 0.010
71%– 100% of 
usual
42 (34) 26 (44) 16 (25)
Liver resection activity
0%– 10% of 
usual
67 (54) 27 (46) 40 (63)
11%– 70% of 
usual
40 (33) 21 (36) 19 (30) 0.096
71%– 100% of 
usual
16 (13) 11 (19) 5 (8)
Lung resection activity
0%– 10% of 
usual
72 (59) 30 (51) 42 (66)
11%– 70% of 
usual
36 (29) 17 (29) 19 (30) 0.026
71%– 100% of 
usual
15 (12) 12 (20) 3 (5)
Neo- adjuvant chemoradiotherapy activity
0%– 10% of 
usual
21 (17) 5 (8) 16 (25)
11%– 70% of 
usual
65 (53) 30 (51) 35 (55) 0.010
71%– 100% of 
usual
37 (30) 24 (41) 13 (20)
Adjuvant chemotherapy activity
0%– 10% of 
usual
22 (18) 6 (10) 16 (25)
11%– 70% of 
usual
79 (64) 14 (24) 40 (63) 0.050
71%– 100% of 
usual
22 (18) 39 (66) 8 (13)
Bold values indicate statistically significant P <0.05.
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F I G U R E  4  The single most important lesson about how to make CRC services as safe and effective as possible for patients during 
the COVID- 19 pandemic (CNS, clinical nurse specialist; FIT, faecal immunochemical testing; MDT, multidisciplinary team; PPE, personal 
protective equipment). (Note: FIT involves the detection of abnormal levels of blood within the stool. Patients with a negative FIT and 
normal haemoglobin with vague symptoms can be reassured that their risk of CRC is very low. In patients with low- risk symptoms but a 
positive FIT test, an urgent referral should be completed. FIT is therefore useful as a triage tool to guide the prioritization of investigations if 
there is limited diagnostic capacity [37,38])



























































































Triage patients according to urgency and individual requirements
Timely diagnosis should continue including FIT testing & endoscopy
Track individual patient progress including delays in pathways
Discuss fewer patients at MDT
New diagnostic pathways
Continue treatment with ‘precautions’ e.g. 2-week pre-operative shielding
Two consultants operating
Continue laparoscopic surgery with adequate precautions 
Appropriate counselling and consenting
Maintain CNS capacity
Pre-operative testing of patients and healthcare staff
COVID risk minimisation
Use of ‘cold’ sites including private facilities where available
Maintenance of cancer capacity during pandemic
Regional coordination with establishment of central cancer hubs
Telephone consultations and virtual clinics
Separation of emergency and elective work
Reorganisation of existing facilities
Communication and coordination
Virtual system (e.g. electronic) for communication
Flexible working important
Clear leadership structure
Clinical enagement with operational teams
Forward planning
Safety first
Avoid ‘egos’ getting in the way
Clinicians should be in the lead
Local audit
Motivate work force
Move from consultant to team-ownership
PPE
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CONCLUSION
As many countries are experiencing subsequent waves of the COVID- 19 
pandemic, it is vital that CRC services are protected and maintained in 
addition to tackling the existing shortfall in diagnostics and treatment 
from the first peak of the pandemic. The use of ‘cold sites’, particularly 
in regions with high rates of COVID- 19, appears to be pivotal for both 
surgical and diagnostic capacity, and highlights the need for regional 
coordination and cooperation as well as the importance of human fac-
tors such as clear communication and strong leadership.
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APPENDIX 1
ITEMS INCLUDED IN THE NATIONAL SURVE Y OF ALL NHS ENG LISH HOSPITAL TRUS TS AND WEL SH HOSPITAL 
BOARDS PROVIDING COLOREC TAL C ANCER (CRC) SERVICE S .
1. In the middle of April, how many bowel cancer patients were referred to your MDT1  via the 2- week wait route compared to normal?
As many or almost as many as usual (91 to 100% of usual)
Small reduction in numbers (71 to 90% of usual)
Large reduction in numbers (20 to 70% of usual)
Very few 2- week wait referrals (0 to 19% of usual)
2. In the middle of April, how many patients at your MDT experienced each of 
the following changes to planned bowel cancer treatment because of the 
COVID−19 pandemic?
All or almost all patients (91 to 100%)
Majority of patients (51 to 90%)
Minority of patients (11 to 50%)
Almost none or none (0 to 10%)i. Treatments delayed because the patient was diagnosed with COVID−19
ii. Delays in tissue diagnosis and/or staging investigations
iii. Treatment plans altered to reflect increased risks from COVID−19 during 
epidemic
iv. Delays in treatment due to risk of COVID−19 infection to patient
v. Delays in treatment due to diversion of healthcare resources for COVID−19 care/
preparation
vi. Temporising treatments used e.g. stent, rectal radiotherapy and long wait
vii. Emergency admissions while patients waited for diagnosis and/or treatment
viii. Changes in lengths of treatment and/or choices of chemotherapy
ix. Deaths due to complications of COVID−19
3. In the middle of April, how were each of the following services (on- or off- site) affected for elective bowel cancer patients at your 
MDT?
i. Diagnostic colonoscopy Stopped entirely (0 to 10% of usual numbers)
Substantially reduced (11 to 70% of usual 
numbers)
Continued more or less the same as before 





v. Neo- adjuvant chemoradiotherapy
vi. Adjuvant chemotherapy
4. In the middle of April, did your MDT have access to a COVID−19 ‘cold site’ for elective colorectal surgery?
No
Yes within every hospital in the trust
Yes in certain hospitals in the trust
5. If you answered ‘Yes in certain hospitals in the trust’ or ‘Yes in another trust/private hospital’, please write the name(s) of these 
specific hospital sites in the box below.
6. What would you describe as the single most important lesson your MDT has learned about how to make services for bowel cancer 
patients as safe and effective as possible during the pandemic?
NOTE: 1 Multidisciplinary team (MDT): group of CRC experts based within a hospital who discuss and plan the treatment of every CRC 
patient. The team contains surgeons, medical doctors, nurses, radiologists, and pathologists. Patients from smaller hospitals will be discussed 
in the closest specialist CRC MDT.
